#United States #New York #Class Action #Gross Law Firm #Baxter International

Investors Encouraged to Join Baxter International Class Action

The Gross Law Firm has issued an important reminder to shareholders of Baxter International, Inc. (NYSE: BAX) regarding a pressing lead plaintiff deadline set for December 15, 2025. This notice is particularly directed towards those who purchased shares during the specified class period from February 23, 2022, to July 30, 2025. Shareholders potentially eligible for this class action are urged to connect with the firm to discuss their options, including the possibility of being appointed as the lead plaintiff.

Background of the Case

The allegations outlined in the impending lawsuit are quite serious, focusing on product failures associated with Baxter's newly launched product, the Novum Large Volume Pump (LVP). According to the complaint, there are claims that Baxter did not adequately address systemic defects within this product, which led to significant malfunctions. These issues reportedly included underinfusion, overinfusion, and complete failure to deliver fluids, potentially endangering patient safety and wellbeing.

Additionally, the lawsuit claims that Baxter was already aware of various malfunctions leading to severe injuries and even fatalities arising from the use of the Novum LVP. The firm asserts that despite being notified of these critical issues, Baxter's attempts to mitigate the risks through customer alerts were insufficient, as the fundamental design flaws persisted, causing continued harm to patients. The consequences of such negligence could have dire implications, not only affecting patient care but also posing a major threat to Baxter's market reputation and financial stability.

Sharply contrasting earlier claims made by Baxter regarding the safety and effectiveness of the Novum LVP, the lawsuit brings to light the seriousness of the information that was allegedly concealed from investors and the public. The company’s statements regarding product rollout, customer feedback, and sales prospects were claimed to be materially false and misleading, creating an artificial inflation of stock price based on unfounded assurances.

Importance of Acting Quickly

As outlined by the Gross Law Firm, shareholders are strongly encouraged to act promptly by registering to be part of this class action. Successful registration as a claimant does not obligate them to pay any fees or costs upfront, and the law firm pledges to keep enrolled shareholders informed via portfolio monitoring software, providing essential updates as the case progresses.

The deadline for taking part in this class action as a lead plaintiff is stated clearly as December 15, 2025. Time is of the essence, and shareholders are invited to explore their rights and options thoroughly before this deadline passes. Participating in this legal endeavor might provide an opportunity for recovery for investors who experienced damages due to Baxter’s alleged misrepresentations.

Why Choose Gross Law Firm?

The Gross Law Firm is a nationally recognized entity specializing in class action lawsuits, with a focused mission of safeguarding investors' rights who have suffered losses due to fraudulent practices. With a commitment to transparency and good corporate governance, the firm aims to hold companies accountable for their actions and ensure that those harmed by deceitful corporate behavior are given a voice. They strive to facilitate recovery for investors whose financial portfolios have been adversely impacted by the misleading statements of corporations like Baxter International.

As the landscape of corporate law continues to evolve, insights from cases like this highlight the critical importance of investor vigilance and legal recourse in safeguarding their financial interests. Further information can be accessed through their official communication channels, where shareholders can submit inquiries and keep abreast of developments related to their case.

Contact Information:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Shareholders of Baxter International, Inc. are encouraged to act before the upcoming deadline to secure their chances for potential recovery in this urgent matter.